Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027 [Yahoo! Finance]
Cardiol Therapeutics Inc. - Class A Common Shares (CRDL)
Company Research
Source: Yahoo! Finance
New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025. Next-generation therapy CRD-38 for heart failure funded through to clinical development, with partnership discussions advancing with leading pharmaceutical companies. Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) Cardiol " or the " Company "), a clinical-stage life sciences company advancing late-stage, anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the successful completion of a private placement offering (the " Offering ") of units (" Units ") for net proceeds of US$11 million. The initial closing of US$10 million has been completed, with the remaining US$1 million to close on Monday, October 20, 2025. "As recruitment in our pivotal Phase III MAVERIC trial gains momentum, with sever
Show less
Read more
Impact Snapshot
Event Time:
CRDL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDL alerts
High impacting Cardiol Therapeutics Inc. - Class A Common Shares news events
Weekly update
A roundup of the hottest topics
CRDL
News
- Cardiol Therapeutics (NASDAQ:CRDL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 [Yahoo! Finance]Yahoo! Finance
- Cardiol Therapeutics (NASDAQ:CRDL) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.MarketBeat
CRDL
Analyst Actions
- 12/1/25 - HC Wainwright
CRDL
Sec Filings
- 12/1/25 - Form 6-K
- 11/13/25 - Form 6-K
- 11/5/25 - Form SUPPL
- CRDL's page on the SEC website